

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005


Docket No.: 49662(72021)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Previously Presented) A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

Ar is phenyl, 1- or 2-naphthyl, each of which is mono-, di-, or tri-substituted;

R₁ is chosen from hydrogen, halogen, cyano, nitro, alkyl, alkenyl, alkoxy, (cycloalkyl)alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or mono- or dialkylcarboxamide each of which is optionally substituted with 0-3 substituents independently selected from Halogen, cyano, hydroxyl, amino, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆aminoalkyl, carboxamido, and benzyl;

R₃ is chosen from hydrogen, cyano, nitro, alkyl, alkenyl, alkoxy, (cycloalkyl)alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or mono- or dialkylcarboxamide, each of which is optionally substituted with 0-3 substituents independently selected from Halogen, cyano, hydroxyl, amino, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆aminoalkyl, carboxamido, and benzyl, with the proviso that R₁ and R₃ are not both hydrogen; and


R₂ is alkenyl, alkynyl, aminoalkyl, mono or dialkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, or mono or dialkylcarboxamide each of which is optionally substituted with 0-3 substituents independently selected from Halogen, cyano, hydroxyl, amino, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆aminoalkyl, carboxamido, and benzyl.

2. (Cancelled).

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

3. (Currently Amended) A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein:

R_1 and R_3 are independently selected from hydrogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, $(C_{3-7}$ cycloalkyl) C_{1-4} alkyl, $(C_{3-7}$ cycloalkyl) C_{2-4} alkenyl, $-O(C_{3-7}$ cycloalkyl) C_{1-4} alkyl, $-O(C_{3-7}$ cycloalkyl) C_{2-4} alkenyl, halo(C_{1-6})alkyl, halo C_{2-6} alkenyl, $-O$ (halo(C_{1-6})alkyl), $-O$ (halo(C_{2-6})alkenyl), $-O(C_{1-6}$ alkyl), $-O(C_{2-6}$ alkenyl), $S(O)_n(C_{1-6}$ alkyl), and $S(O)_n(C_{2-6}$ alkenyl),

where each alkyl, or alkenyl is independently straight, branched, or cyclic, and is optionally substituted with one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino,

and

where each C_{3-7} cycloalkyl is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino,

with the proviso that not both R_1 and R_3 are hydrogen;

R_2 is selected from the group consisting of $-OR_A$, $-S(O)_nR_A$, $-NHR_A$, $-NR_AR_B$, $-C(=O)NHR_A$, $-C(=O)NR_AR_B$, $-S(O)_nNHR_A$, $-S(O)_nNR_AR_B$, $-NHC(=O)R_A$, $-NR_AR_BC(=O)R_A$, $-NHS(O)_nR_A$, $-NR_BS(O)_nR_A$, and 3- to 7-membered carbocyclic groups which are saturated or partially unsaturated, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, C_{1-4} alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)(C_{1-4} alkyl), and $-S(O)_n$ (alkyl);

Ar is selected from the group consisting of phenyl and naphthyl, each of which is mono-, di-, or tri-substituted with R_C ;

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

R_A and R_B , which may be the same or different, are independently selected at each occurrence from:

hydrogen, straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, each of which may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, cyano, amino, C_{1-6} alkoxy, $-NH(C_{1-6}alkyl)$, $-N(C_{1-6}alkyl)(C_{1-6}alkyl)$, $-NHC(=O)(C_{1-6}alkyl)$, $-N(C_{1-6}alkyl)C(=O)(C_{1-6}alkyl)$, $-NHS(O)_n(C_{1-6}alkyl)$, $-S(O)_n(C_{1-6}alkyl)$, $-S(O)_nNH(C_{1-6}alkyl)$, $-S(O)_nN(C_{1-6}alkyl)(C_{1-6}alkyl)$, and 3- to 7-membered carbocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, $C_{1-4}alkyl$, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, and $-S(O)_n(alkyl)$;

R_C is independently selected at each occurrence from halogen, cyano, halo(C_{1-6})alkyl, halo(C_{1-6})alkoxy, hydroxy, amino, C_{1-6} alkyl substituted with 0-2 R_D , C_{2-6} alkenyl substituted with 0-2 R_D , C_{2-6} alkynyl substituted with 0-2 R_D , C_{3-7} cycloalkyl substituted with 0-2 R_D , $(C_{3-7}cycloalkyl)C_{1-4}alkyl$ substituted with 0-2 R_D , C_{1-6} alkoxy substituted with 0-2 R_D , $-NH(C_{1-6}alkyl)$ substituted with 0-2 R_D , $-N(C_{1-6}alkyl)(C_{1-6}alkyl)$ each $C_{1-6}alkyl$ independently substituted with 0-2 R_D , $-XR_A$, and Y ;

R_D is independently selected at each occurrence from the group consisting of halogen, hydroxy, cyano, amino, $C_{1-4}alkyl$, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$,

$-S(O)_n(alkyl)$, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, $CO(C_{1-4}alkyl)$, $CONH(C_{1-4}alkyl)$, $CON(C_{1-4}alkyl)(C_{1-4}alkyl)$, $-XR_A$, and Y ;

X is independently selected at each occurrence from the group consisting of $-CH_2-$, $-CHR_B-$, $-O-$, $-C(=O)-$, $-C(=O)O-$, $-S(O)_n-$, $-NH-$, $-NR_B-$, $-C(=O)NH-$, $-C(=O)NR_B-$, $-S(O)_nNH-$, $-S(O)_nNR_B-$, $-OC(=S)S-$, $-NHC(=O)-$, $-NR_BC(=O)-$, $-NHS(O)_n-$, $-OSiH_n(C_{1-4}alkyl)_{2-n}-$, and $-NR_BS(O)_n-$;

Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

Y is independently selected at each occurrence from: 3- to 7-membered carbocyclic groups or heterocyclic groups which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, cyano, C₁₋₄alkyl, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), and -S(O)_n(alkyl),

said 3- to 7-membered heterocyclic groups containing one or more heteroatom(s) independently selected from N, O, and S, with the point of attachment being either carbon or nitrogen; and
n is independently selected at each occurrence from 0, 1, and 2.

4. (Previously Presented) A compound or salt according to Claim 1,
wherein

Ar is mono-, di-, or trisubstituted phenyl; and

R₂ is selected from aminoalkyl, and mono or dialkylamino.

5. (Original) A compound or salt according to Claim 3, wherein:
Ar is phenyl mono-, di-, or tri-substituted with R_C.

6. (Previously Presented) A compound or salt according to Claim 3,
wherein:
Ar is phenyl mono-, di-, or tri-substituted with R_C; and
R₁ and R₃ are independently selected from the group consisting of
C₁₋₃alkyl, C₁₋₃alkoxy, (C₃₋₇cycloalkyl)C₁₋₃alkyl, (C₃₋₇cycloalkyl)C₁₋₃alkoxy, each of
which is unsubstituted or substituted by 1-3 groups independently chosen from hydroxy,
amino, cyano, and halogen.

7. (Previously Presented) A compound or salt according to Claim 3,
wherein:
Ar is phenyl mono-, di-, or tri-substituted with R_C; and
R_A and R_B, which may be the same or different, are independently selected at
each occurrence from:

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

straight, branched, or cyclic alkyl groups having from 1 to 8 carbon atoms,
 straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or
 straight or branched alkynyl groups consisting of 2 to 8 carbon atoms.


8. (Previously Presented) A compound or salt according to Claim 3,
 wherein:

Ar is phenyl mono-, di-, or tri-substituted with R_C;

R_A and R_B, which may be the same or different, are independently selected at
 each occurrence from: straight, branched, or cyclic alkyl groups having from 1 to 8
 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon
 atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms; and

R₁ and R₃ are independently selected from the group consisting of C₁₋₃alkyl, C₁₋₃
 alkoxy, (C₃₋₇cycloalkyl)C₁₋₃alkyl, (C₃₋₇cycloalkyl)C₁₋₃alkoxy, each of which is
 unsubstituted or substituted by 1-3 groups independently chosen from hydroxy, amino,
 cyano, and halogen.

9. (Previously Presented) A compound of Formula A



Formula A

or a pharmaceutically acceptable salt thereof, wherein:

R_x and R_y are the same or different and are independently selected from:

- a) hydrogen,
- b) -(C=O)alkyl_A, wherein alkyl_A is a straight or branched alkyl group
 having from 1 to 8 carbon atoms;
- c) straight, branched, or cyclic alkyl groups consisting of 1 to 8
 carbon atoms, cycloalkyl(alkyl) groups consisting of 4 to 11 carbon atoms,
 straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon
 atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon

Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

atoms, each of which may be further substituted with one or more substituent(s) independently selected from:

- i) hydroxy, halogen, amino, cyano, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-NH(C_{1-4}alkyl)(C_{1-4}alkyl)$, and
- ii) 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents independently selected from halogen, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, oxo, hydroxy, amino, $C_{1-4}alkyl$, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, and $-S(O)_n(alkyl)$,

R_1 is selected from hydrogen, halogen, cyano, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-O(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, halo(C_{1-6})alkyl, halo(C_{2-6})alkenyl, $-O(halo(C_{1-6})alkyl)$, $-O(halo(C_{2-6})alkenyl)$, $-O(C_{1-6}alkyl)$, $-O(C_{2-6}alkenyl)$, $S(O)_n(C_{1-6}alkyl)$, and $S(O)_n(C_{2-6}alkenyl)$,

R_3 is selected from hydrogen, cyano, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-O(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, halo(C_{1-6})alkyl, halo(C_{2-6})alkenyl, $-O(halo(C_{1-6})alkyl)$, $-O(halo(C_{2-6})alkenyl)$, $-O(C_{1-6}alkyl)$, $-O(C_{2-6}alkenyl)$, $S(O)_n(C_{1-6}alkyl)$, and $S(O)_n(C_{2-6}alkenyl)$,

where each alkyl, or alkenyl is independently straight, branched, or cyclic, and is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, $C_{1-4}alkoxy$, amino, and mono- or di(C_{1-4})alkylamino,

and

where said $C_{3-7}cycloalkyl_1$ is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, $C_{1-4}alkoxy$, amino, and mono- or di(C_{1-4})alkylamino with the proviso that not both R_1 and R_3 are hydrogen;

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

Ar is selected from the group consisting of phenyl and naphthyl, each of which is mono-, di-, or tri-substituted with R_C;

R_A and R_B, which may be the same or different, are independently selected at each occurrence from the group consisting of:

hydrogen, straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, and straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, each of which may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, nitro, cyano, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), -NHC(=O)(C₁₋₆alkyl), -N(C₁₋₆alkyl)C(=O)(C₁₋₆alkyl), -NHS(O)_n(C₁₋₆alkyl), -S(O)_n(C₁₋₆alkyl), -S(O)_nNH(C₁₋₆alkyl), -S(O)_nN(C₁₋₆alkyl)(C₁₋₆alkyl), and Z;

R_C is independently selected at each occurrence from halogen, cyano, halo(C₁₋₆alkyl), halo(C₁₋₆alkoxy), hydroxy, amino, and C₁₋₆alkyl substituted with 0-2 R_D, C₂₋₆ alkenyl substituted with 0-2 R_D, C₂₋₆alkynyl substituted with 0-2 R_D, C₃₋₇cycloalkyl substituted with 0-2 R_D, (C₃₋₇cycloalkyl)C₁₋₄alkyl substituted with 0-2 R_D, C₁₋₆alkoxy substituted with 0-2 R_D, -NH(C₁₋₆alkyl) substituted with 0-2 R_D, -N(C₁₋₆alkyl)(C₁₋₆alkyl) each C₁₋₄alkyl independently substituted with 0-2 R_D, -XR_A, and Y, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the pyrimidine ring shown in Formula A is substituted;

R_D is independently selected at each occurrence the group consisting of halogen, hydroxy, cyano, C₁₋₄alkyl, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), -S(O)_n(alkyl) halo(C₁₋₄alkyl), halo(C₁₋₄alkoxy), CO(C₁₋₄alkyl), CONH(C₁₋₄alkyl), CON(C₁₋₄alkyl)(C₁₋₄alkyl), -XR_A, and Y;

X is independently selected at each occurrence from the group consisting of -CH₂-, -CHR_B-, -O-, -C(=O)-, -C(=O)O-, -S(O)_n-, -NH-, -NR_B-, -C(=O)NH-, -C(=O)NR_B-, -S(O)_nNH-, -S(O)_nNR_B-, -OC(=S)S-, -NHC(=O)-, -NR_BC(=O)-, -NHS(O)_n-, -OSiH_n(C₁₋₄alkyl)_{2-n}-, and -NR_BS(O)_n-;

Y and Z are independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic groups or heterocyclic groups, which

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, and $-S(O)_n(alkyl)$; and n is 0, 1, or 2.

10. (Previously Presented) A compound or salt according to Claim 9, wherein:

R_X and R_Y are the same or different and are independently selected from:

a) $-(C=O)alkyl_A$, wherein $alkyl_A$ is a straight or branched alkyl group having from 1 to 8 carbon atoms;

b) straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 12 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, each of which may be further substituted with one or more substituent(s) independently selected from:

i) hydroxy, halogen, amino, cyano, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-NH(C_{1-4}alkyl)(C_{1-4}alkyl)$, and

ii) 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents independently selected from halogen, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, and $-S(O)_n(alkyl)$.

R_1 is selected from hydrogen, halogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-O(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, halo(C_{1-6})alkyl, halo C_{2-6} alkenyl, $-O(halo(C_{1-6})alkyl)$, $-O(halo(C_{2-6})alkenyl)$, $-O(C_{1-6}alkyl)$, and $-O(C_{2-6}alkenyl)$.

R_3 is selected from hydrogen, cyano, C_{1-6} alkyl, C_{2-6} alkenyl, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-$

Docket No.: 49662(72021)

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

$_4$ alkyl), halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, CO(C_{1-4} alkyl), CONH(C_{1-4} alkyl), CON(C_{1-4} alkyl)(C_{1-4} alkyl), $-XR_A$, and Y;

X is independently selected at each occurrence from the group consisting of $-CH_2-$, $-CHR_B-$, $-O-$, $-C(=O)-$, $-C(=O)O-$, $-NH-$, $-NR_B-$, $-C(=O)NH-$, $-C(=O)NR_B-$, $-NHC(=O)-$, and $-NR_BC(=O)-$;

Y and Z are independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), and $-N(C_{1-4}$ alkyl)(C_{1-4} alkyl); and

n is 0, 1, or 2.

11. (Previously Presented) A compound or salt according to claim 9, wherein:

Ar is phenyl mono-, di-, or tri-substituted with R_C , and

R_1 is selected from the group consisting of

hydrogen, halogen, C_{1-4} alkoxy, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, C_{1-6} alkyl, which C_{1-6} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino, and

(C_{3-7} cycloalkyl) C_{1-4} alkyl, which (C_{3-7} cycloalkyl) C_{1-4} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino; and

R_3 is selected from the group consisting of

hydrogen, C_{1-4} alkoxy, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, C_{1-6} alkyl, which C_{1-6} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino, and

(C_{3-7} cycloalkyl) C_{1-4} alkyl, which (C_{3-7} cycloalkyl) C_{1-4} alkyl is unsubstituted or substituted by one to three substituents independently


Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

selected from hydroxy, oxo, cyano, C₁₋₄alkoxy, amino, and mono- or di(C₁₋₄alkylamino).

12. (Previously Presented) A compound or salt according to claim 9, wherein:

Ar is a phenyl group of the formula:



wherein L indicates a bond to the pyrimidine ring in Formula A

and the phenyl group is substituted at one, two, or three of positions 2, 4, and 6 positions of the phenyl ring with substituents independently selected from:

- i) halogen, cyano, halo(C₁₋₄alkyl), halo(C₁₋₄alkoxy), hydroxy, amino, C₁₋₆ alkyl, C₁₋₆alkoxy, (C₁₋₄alkoxy)C₁₋₄alkoxy, and mono- or di(C₁₋₄alkyl)amino,
- ii) C₁₋₆ alkyl and C₁₋₆alkoxy which are further substituted with a 3- to 7-membered carbocyclic group, which is saturated, unsaturated, or aromatic, which 3- to 7-membered carbocyclic and heterocyclic group may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C₁₋₄alkyl, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), and -N(C₁₋₄alkyl)(C₁₋₄alkyl).

13. (Previously Presented) A compound or salt according to claim 9, wherein:

Ar is phenyl mono-, di-, or tri-substituted with R_C,

R_X and R_Y, which may be the same or different, are independently selected at each occurrence from

straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms;


Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

R_1 is selected from the group consisting of hydrogen, halogen, C_{1-4} alkoxy, halo(C_{1-4})alkyl, (halo(C_{1-4})alkoxy, C_{1-6} alkyl, which C_{1-6} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino, (C_{3-7} cycloalkyl) C_{1-4} alkyl, which (C_{3-7} cycloalkyl) C_{1-4} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino; and

R_3 is selected from the group consisting of hydrogen, C_{1-4} alkoxy, halo(C_{1-4})alkyl, (halo(C_{1-4})alkoxy, C_{1-6} alkyl, which C_{1-6} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino, (C_{3-7} cycloalkyl) C_{1-4} alkyl, which (C_{3-7} cycloalkyl) C_{1-4} alkyl is unsubstituted or substituted by one to three substituents independently selected from hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino.


14. (Previously Presented) A compound or salt according to claim 9 of the formula:



R_X and R_Y are the same or different and are independently selected from the group consisting of:

hydrogen and $C_1 - C_6$ alkyl.

15. (Previously Presented) A compound or salt according to the formula



Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

wherein:

R_x is chosen from

straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 12 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, each of which may be further substituted with one or more substituent(s) independently selected from:

(a) hydroxy, halogen, amino, cyano, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-NH(C_{1-4}alkyl)(C_{1-4}alkyl)$, and

(b) 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents selected from halogen, halo(C_{1-4})alkyl, oxo, hydroxy, amino, $C_{1-4}alkyl$, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$,

R_1 is selected from hydrogen, halogen, cyano, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-O(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, halo(C_{1-6})alkyl, halo $C_{2-6}alkenyl$, $-O(halo(C_{1-6})alkyl)$, $-O(halo(C_{2-6})alkenyl)$, $-O(C_{1-6}alkyl)$, $-O(C_{2-6}alkenyl)$, $S(O)_n(C_{1-6}alkyl)$, and $S(O)_n(C_{2-6}alkenyl)$,

R_3 is selected from hydrogen, cyano, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, $-O(C_{3-7}cycloalkyl_1)C_{1-4}alkyl$, $-O(C_{3-7}cycloalkyl_1)C_{2-4}alkenyl$, halo(C_{1-6})alkyl, halo $C_{2-6}alkenyl$, $-O(halo(C_{1-6})alkyl)$, $-O(halo(C_{2-6})alkenyl)$, $-O(C_{1-6}alkyl)$, $-O(C_{2-6}alkenyl)$, $S(O)_n(C_{1-6}alkyl)$, and $S(O)_n(C_{2-6}alkenyl)$,

where each alkyl, or alkenyl is independently straight, branched, or cyclic, and is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, $C_{1-4}alkoxy$, amino, and mono- or di($C_{1-4}alkylamino$,

and

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

where said C_{3-7} cycloalkyl₁ is optionally substituted by one or more substituents independently chosen from halogen, hydroxy, oxo, cyano, C_{1-4} alkoxy, amino, and mono- or di(C_{1-4})alkylamino with the proviso that not both R_1 and R_3 are hydrogen;

Ar is selected from the group consisting of phenyl and naphthyl, each of which is mono-, di-, or tri-substituted with R_C ;

R_A and R_B , which may be the same or different, are independently selected at each occurrence from the group consisting of:

hydrogen, straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, and straight or branched alkynyl groups consisting of 2 to 8 carbon atoms; each of which may be further substituted with one or more substituent(s) independently selected from oxo, hydroxy, halogen, nitro, cyano, C_{1-6} alkoxy, - $NH(C_{1-6}alkyl)$, - $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, - $NHC(=O)(C_{1-6}alkyl)$, - $N(C_{1-6}alkyl)C(=O)(C_{1-6}alkyl)$, - $NHS(O)_n(C_{1-6}alkyl)$, - $S(O)_n(C_{1-6}alkyl)$, - $S(O)_nNH(C_{1-6}alkyl)$, - $S(O)_nN(C_{1-6}alkyl)(C_{1-6}alkyl)$, and Z ;

R_C is independently selected at each occurrence from halogen, cyano, halo(C_{1-6})alkyl, halo(C_{1-6})alkoxy, hydroxy, amino, and C_{1-6} alkyl substituted with 0-2 R_D , C_{2-6} alkenyl substituted with 0-2 R_D , C_{2-6} alkynyl substituted with 0-2 R_D , C_{3-7} cycloalkyl substituted with 0-2 R_D , (C_{3-7} cycloalkyl) C_{1-4} alkyl substituted with 0-2 R_D , C_{1-6} alkoxy substituted with 0-2 R_D , - $NH(C_{1-6}alkyl)$ substituted with 0-2 R_D , - $N(C_{1-6}alkyl)(C_{1-6}alkyl)$ each C_{1-4} alkyl independently substituted with 0-2 R_D , - XR_A , and Y , with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the pyrimidine ring shown in Formula A is substituted;

R_D is independently selected at each occurrence the group consisting of halogen, hydroxy, cyano, C_{1-4} alkyl, - $O(C_{1-4}alkyl)$, - $NH(C_{1-4}alkyl)$, - $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, - $S(O)_n(alkyl)$ halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, $CO(C_{1-4}alkyl)$, $CONH(C_{1-4}alkyl)$, $CON(C_{1-4}alkyl)(C_{1-4}alkyl)$, - XR_A , and Y ;

X is independently selected at each occurrence from the group consisting of - CH_2 -, - CHR_D -, - O -, - $C(=O)$ -, - $C(=O)O$ -, - $S(O)_n$ -, - NH -, - NR_B -, - $C(=O)NH$ -, -

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

$C(=O)NR_D$ -, $-S(O)_nNH$ -, $-S(O)_nNR_B$ -, $-OC(=S)S$ -, $-NHC(=O)$ -, $-NR_BC(=O)$ -, $-NHS(O)_n$ -, $-OSiH_n(C_{1-4}alkyl_{2-n})$ -, and $-NR_BS(O)_n$;

Y and Z are independently selected at each occurrence from the group consisting of: 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, $C_{1-4}alkyl$, $-O(C_{1-4}alkyl)$,

$-NH(C_{1-4}alkyl)$, $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$, and $-S(O)_n(alkyl)$; and


n is 0, 1, or 2.

16. (Previously Presented) A compound or salt according to claim 15 wherein:

R_1 is selected from the group consisting of hydrogen, halogen, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, and $halo(C_{1-4}alkyl)$; and

R_3 is selected from the group consisting of hydrogen, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, and $halo(C_{1-4}alkyl)$.

17. (Previously Presented) A compound or salt according to Claim 3 of Formula B:



Formula B

wherein

Ar is phenyl mono-, di-, or tri-substituted with R_C ;

R is selected from straight, branched, or cyclic alkyl groups, (cycloalkyl)alkyl groups, or straight, branched, or cyclic alkenyl groups, and which are by one or more substituents independently chosen from oxo, hydroxy, halogen, cyano, $-O(C_{1-4}alkyl)$, amino, $-NH(C_{1-4}alkyl)$, and $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$;


Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

R_1 is selected from hydrogen, halogen, cyano, C_{1-4} alkyl, (C_{3-7} cycloalkyl) C_{1-4} alkyl, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, and $-O(C_{1-4}$ alkyl); and R_x and R_y are the same or different and are independently selected from:

- a) hydrogen,
- b) $-(C=O)alkyl_A$, wherein $alkyl_A$ is a straight or branched alkyl group having from 1 to 8 carbon atoms;
- c) straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, each of which may be further substituted with one or more substituent(s) independently selected from (i) hydroxy, halogen, amino, cyano, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), and $-NH(C_{1-4}$ alkyl)(C_{1-4} alkyl), and (ii) 3- to 7-membered carbocyclic groups, which are saturated, unsaturated, or aromatic, which may be substituted with one or more substituents selected from halogen, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}$ alkyl), $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl)(C_{1-4} alkyl), and $-S(O)_n(alkyl)$.

18. (Withdrawn) A compound or salt according to Claim 17, wherein Ar is a phenyl group of the formula:



wherein L indicates a bond to the pyrimidine ring in Formula B

and the Ar phenyl group is substituted at one, two, or three of positions 2, 4, and 6 with substituents independently selected from:

- i) halogen, cyano, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, hydroxy, amino, C_{1-6} alkyl, C_{1-6} alkoxy, (C_{1-4} alkoxy) C_{1-4} alkoxy, and mono- or di(C_{1-4} alkyl)amino,
- ii) C_{1-6} alkyl and C_{1-6} alkoxy which are further substituted with a 3- to 7-membered carbocyclic group, which is saturated, unsaturated, or aromatic, which 3- to 7-


Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

membered carbocyclic group may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$.

19. (Withdrawn) A compound or salt according to Claim 17,
 wherein

Ar is a phenyl group of the formula:



wherein L indicates a bond to the pyrimidine ring in Formula B

and the Ar phenyl group is substituted at one, two, or three of
 positions 2, 4, and 6 with substituents independently selected from:

i) halogen, cyano, halo(C_{1-4})alkyl, halo(C_{1-4})alkoxy, hydroxy, amino, C_{1-6} alkyl, C_{1-6} alkoxy, (C_{1-4} alkoxy) C_{1-4} alkoxy, and mono- or di(C_{1-4} alkyl)amino,

ii) C_{1-6} alkyl and C_{1-6} alkoxy which are further substituted with a 3- to 7-membered carbocyclic group, which is saturated, unsaturated, or aromatic, which 3- to 7-membered carbocyclic group may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$;

R_x and R_y are the same or different and are independently selected from the group consisting of:

- a) hydrogen (with the proviso that R_x and R_y are not both hydrogen),
- b) $-(C=O)alkyl_A$, wherein $alkyl_A$ is a straight or branched alkyl group having from 1 to 8 carbon atoms;
- c) straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms, which may be further substituted with one or more substituent(s) independently selected from


Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

hydroxy, halogen, amino, cyano, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-NH(C_{1-4}alkyl)(C_{1-4}alkyl)$.

20. (Withdrawn) A compound or salt according to Claim 17,
 wherein

Ar is a phenyl group of the formula:



wherein L indicates a bond to the pyrimidine ring in Formula B

and the Ar phenyl group is substituted at one, two, or three of
 positions 2, 4, and 6 with substituents independently selected from:

- i) halogen, cyano, halo(C_{1-4} alkyl), halo(C_{1-4} alkoxy), hydroxy, amino, C_{1-6} alkyl, C_{1-6} alkoxy, (C_{1-4} alkoxy) C_{1-4} alkoxy, and mono- or di(C_{1-4} alkyl)amino,
- ii) C_{1-6} alkyl and C_{1-6} alkoxy which are further substituted with a 3- to 7-membered carbocyclic group, which is saturated, unsaturated, or aromatic, which 3- to 7-membered carbocyclic group may be further substituted with one or more substituents independently selected from halogen, oxo, hydroxy, amino, C_{1-4} alkyl, $-O(C_{1-4}alkyl)$, $-NH(C_{1-4}alkyl)$, and $-N(C_{1-4}alkyl)(C_{1-4}alkyl)$;


R_X and R_Y are the same or different and are independently selected from the
 group consisting of:

- a) hydrogen (with the proviso that R_X and R_Y are not both hydrogen),
- b) $-(C=O)alkyl_A$, wherein $alkyl_A$ is a straight or branched alkyl group having from 1 to 8 carbon atoms;
- c) straight, branched, or cyclic alkyl groups consisting of 1 to 8 carbon atoms, (cycloalkyl)alkyl groups consisting of 4 to 11 carbon atoms, straight, branched, or cyclic alkenyl groups consisting of 2 to 8 carbon atoms, or straight or branched alkynyl groups consisting of 2 to 8 carbon atoms.

Application No. 09/811,359
 Amendment dated January 25, 2006
 After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

21. (Withdrawn) A compound or salt according to Claim 17, of the formula:




wherein:

q is an integer from 1 to 4;

G is hydrogen, hydroxy, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), or a 3- to 7-membered carbocyclic group which is saturated, unsaturated, or aromatic, which is unsubstituted or substituted with one or more substituents independently selected from halogen, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, oxo, hydroxy, amino, C₁₋₄alkyl, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), and -S(O)_n(alkyl);

J and K are independently selected from halogen, cyano, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₁₋₄alkyl, C₁₋₄alkoxy, (C₁₋₄alkoxy)C₁₋₄alkoxy, and mono- or di(C₁₋₄alkyl)amino.

22. (Withdrawn) A compound or salt according to Claim 17, of the formula:



Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

wherein:

Q is hydrogen or C₃₋₇ cycloalkyl;

q is an integer from 1 to 4;

G is hydrogen, hydroxy, C₁₋₆alkoxy, -NH(C₁₋₆alkyl), -N(C₁₋₆alkyl)(C₁₋₆alkyl), or a 3- to 7-membered carbocyclic group, which is saturated, unsaturated, or aromatic, which is unsubstituted or substituted with one or more substituents independently selected from halogen, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, oxo, hydroxy, amino, C₁₋₄alkyl, -O(C₁₋₄alkyl), -NH(C₁₋₄alkyl), -N(C₁₋₄alkyl)(C₁₋₄alkyl), and -S(O)_n(alkyl);

J and K are independently selected from halogen, cyano, halo(C₁₋₄)alkyl, halo(C₁₋₄)alkoxy, hydroxy, amino, C₁₋₆alkyl, C₁₋₄alkyl, C₁₋₄alkoxy, (C₁₋₄alkoxy)C₁₋₄alkoxy, and mono- or di(C₁₋₄alkyl)amino; and

R_X and R_Y are the same or different and are independently selected from hydrogen (with the proviso that R_X and R_Y are not both hydrogen) and straight, branched, or cyclic alkyl groups having from 1 to 6 carbon atoms, which alkyl groups may contain one or more double or triple bonds.

23. (Cancelled).

24. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an IC₅₀ value less than or equal to 1 micromolar.

25. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an IC₅₀ value less than or equal to 100 nanomolar.

26. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits an IC₅₀ value less than or equal to 10 nanomolar.

Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

27. (Original) A method for treating an anxiety disorder, a stress-related disorder, or an eating disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.

28-29. (Cancelled).

30. (Original) A compound or salt according to Claim 1, wherein in a standard in vitro Na channel functional assay the compound does not show any statistically significant activity at the $p < 0.05$ level of significance.

31-34. (Cancelled).

35. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of Claim 1.

36-38. (Cancelled).

39. (Withdrawn) A compound according to Claim 1, which is [2-(2,4-dimethoxyphenyl)-4-methoxy-6-methylpyrimidin-5-yl]dipropylamine.

40. (Withdrawn) A compound according to Claim 1, which is [2-(2-chlorophenyl)-4-methoxy-6-methylpyrimidin-5-yl]dipropylamine.

41. (Withdrawn) A compound according to Claim 1, which is [2-(2,4-dichlorophenyl)-4-methoxy-6-methylpyrimidin-5-yl]dipropylamine.

42. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4-chlorophenyl)-4-methoxy-6-methylpyrimidin-5-yl]dipropylamine.

Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

43. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4-isopropylphenyl)-4-methoxy-6-methylpyrimidin-5-yl]dipropylamine.
44. (Withdrawn) A compound according to Claim 1, which is [2-(2,4-dimethoxyphenyl)-4-methoxy-6-methyl pyrimidin-5-yl] dipropylamine.
45. (Withdrawn) A compound according to Claim 1, which is [4-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-6-methylpyrimidin-5-yl]dipropylamine.
46. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-methoxy-6-ethyl pyrimidin-5-yl] dipropylamine.
47. (Withdrawn) A compound according to Claim 1, which is [2-(2,4,6-trimethylphenyl)-4-methoxy-6-methyl pyrimidin-5-yl] dipropylamine.
48. (Withdrawn) A compound according to Claim 1, which is [2-(2,4,6-trimethylphenyl)-4-methoxy-6-ethyl pyrimidin-5-yl] dipropylamine.
49. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-ethoxy-6-methyl pyrimidin-5-yl] dipropylamine.
50. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-(2-fluoroethoxy)-6-methyl pyrimidin-5-yl] dipropylamine.
51. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-isopropoxy-6-methyl pyrimidin-5-yl] dipropylamine.
52. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-methoxy-6-fluoromethyl pyrimidin-5-yl] dipropylamine.

Application No. 09/811,359
Amendment dated January 26, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

53. (Withdrawn) A compound according to Claim 1, which is [2-(2-methoxy-4,6-dimethylphenyl)-4-methoxy-6-difluoromethyl pyrimidin-5-yl] dipropylamine.
54. (Withdrawn) A compound according to Claim 1, which is 1-[5-(dipropylamino)-6-methoxy-2-(2-methoxy-4,6-dimethylphenyl)-pyrimidin-4-yl]-ethan-1-ol.
55. (Withdrawn) A compound according to Claim 1, which is 1-[5-(dipropylamino)-6-methoxy-2-(2-methoxy-4,6-dimethylphenyl)-pyrimidin-4-yl]-propan-2-ol.
56. (Withdrawn) A compound according to Claim 1, which is [4-(2-Cyclopropyl-2-fluoro-ethyl)-6-methoxy-2-(2-methoxy-4,6-dimethyl-phenyl)-pyrimidin-5-yl]-dipropyl-amine.
57. (Withdrawn) A compound according to Claim 1, which is [4-(2-Cyclopropyl-2-hydroxy-ethyl)-6-methoxy-2-(2-methoxy-4,6-dimethyl-phenyl)-pyrimidin-5-yl]-dipropyl-amine.
58. (Withdrawn) A compound according to Claim 1, which is 1-[5-Dipropylamino-6-methoxy-2-(2-methoxy-4,6-dimethyl-phenyl)-pyrimidin-4-ylmethyl]-cyclobutanol.
59. (Withdrawn) A compound according to Claim 1, which is (Cyclopropylmethyl)[4-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-6-methylpyrimidin-5-yl]propylamine.
60. (Withdrawn) A compound according to Claim 1, which is Cyclopropylmethyl-[2-(2-ethoxy-4,6-dimethylphenyl)-4-methoxy-6-methyl pyrimidin-5-yl]propyl-amine.

Application No. 09/811,359
Amendment dated January 25, 2006
After Final Office Action of December 9, 2005

Docket No.: 49662(72021)

61. (Withdrawn) A compound according to Claim 1, which is
Cyclopropylmethyl[2-(2-propoxy-4,6-dimethylphenyl)-4-methoxy-6-methylpyrimidin-5-yl]
dipropylamine.

62. (Withdrawn) A compound according to Claim 1, which is
Cyclopropylmethyl[2-(2-isopropoxy-4,6-dimethylphenyl)-4-methoxy-6-methylpyrimidin-5-
yl] dipropylamine.

63. (Withdrawn) A compound according to Claim 1, which is
Cyclopropylmethyl[2-(2-ethoxymethoxy-4,6-dimethylphenyl)-4-methoxy-6-
methylpyrimidin-5-yl] dipropylamine.

64. (Withdrawn) A compound according to Claim 1, which is [2-
(dimethylamino)ethyl](cyclopropylmethyl)[6-methoxy-2-(6-methoxy-2,4-dimethylphenyl)-
4-methylpyrimidin-5-yl]amine.

65-66. (Cancelled).

67. (Withdrawn) Cyclopropylmethyl-(2-methoxy-ethyl)-[4-methoxy-2-(2-
methoxy-4,6-dimethyl-phenyl)-6-methyl-pyrimidin-5-yl]-amine.

68. (Cancelled).

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**